Humana Inc (HUM) · Oct 9, 2026 · Other events
Top Quartile achieved — BY28 Stars revenue PMPM exceeded the peer median by more than 10%
Humana’s Medicare Advantage ratings beat its Top Quartile target for 2028, creating a potential one-time benefit while 2026 EPS guidance stays unchanged.
Humana is rebuilding its Medicare Advantage earnings engine after a Star Ratings-driven 2026 headwind, with management’s longer-term plan centered on restoring Top Quartile performance by Bonus Year 2028. The ratings recovery arrived ahead of the key deadline. Based on final 2027 MA Star Ratings, Humana says it exceeded its Top Quartile goal, defined as Stars revenue per member per month at least 10% above the peer median. 〔0〕 That is more meaningful than simply improving from a weak base: it suggests the quality-bonus economics underpinning the 2028 recovery plan are now tracking above the company’s own target, not merely toward it.
| Item | Filing detail |
|---|---|
| Top Quartile definition | Stars revenue PMPM at least 10% above peer median |
| FY 2026 adjusted EPS guidance | At least $9.00 |
| Expected benefit timing | 2028, with some outperformance potentially one-time |
This is a business-story upgrade, not a 2026 earnings raise. Humana reaffirmed adjusted EPS guidance of at least $9.00, which was already in place, so the immediate profit outlook is unchanged. The value is instead in improving the credibility of the 2028 earnings framework: stronger Stars performance can support higher rebates and quality payments, although the eventual dollar benefit still depends on membership, contract mix, risk scores, benchmarks, rebates, and competitive pricing.
The company is deliberately treating part of the upside as temporary. Humana says some BY28 outperformance versus Top Quartile will be one-time and expects to direct that benefit toward investments and shareholder returns, while warning that its GAAP EPS guidance may still change as strategic initiatives are completed. 〔1〕 The next substantive checkpoint is the December 10, 2026 investor update, when management plans to quantify how this ratings result fits into its 2028 earnings plan.
Bottom line: Humana has cleared the central quality hurdle in its recovery plan earlier and better than expected, but the filing does not increase 2026 earnings guidance. It materially strengthens the 2028 story while leaving the size and durability of the benefit to be quantified later.
December 10 investor update
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!